ProQR Therapeutics (NASDAQ:PRQR) Raised to “Hold” at StockNews.com

ProQR Therapeutics (NASDAQ:PRQR) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also recently weighed in on the stock. Citigroup upped their price objective on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of ProQR Therapeutics in a research note on Friday, May 10th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $2.50 target price on shares of ProQR Therapeutics in a research note on Friday, May 10th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $3.38.

ProQR Therapeutics Stock Up 0.6 %

PRQR opened at $1.66 on Friday. ProQR Therapeutics has a twelve month low of $1.11 and a twelve month high of $3.29. The company has a 50-day simple moving average of $1.88 and a 200 day simple moving average of $2.04. The stock has a market capitalization of $135.06 million, a price-to-earnings ratio of -4.49 and a beta of 0.35.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. ProQR Therapeutics had a negative net margin of 260.75% and a negative return on equity of 61.58%. The business had revenue of $4.83 million during the quarter, compared to analysts’ expectations of $3.31 million. Sell-side analysts anticipate that ProQR Therapeutics will post -0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On ProQR Therapeutics

A number of hedge funds have recently modified their holdings of the business. Ikarian Capital LLC boosted its holdings in ProQR Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after acquiring an additional 10,958 shares during the last quarter. BNP Paribas Financial Markets increased its position in ProQR Therapeutics by 120.1% during the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 19,100 shares during the period. RFG Advisory LLC acquired a new stake in ProQR Therapeutics during the 1st quarter valued at approximately $73,000. Acadian Asset Management LLC acquired a new stake in ProQR Therapeutics during the 1st quarter valued at approximately $56,000. Finally, EP Wealth Advisors LLC acquired a new stake in ProQR Therapeutics during the 1st quarter valued at approximately $26,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).